导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.26% | 2774/4773 |
| 近一周 | -1.80% | 2863/5465 |
| 近一月 | -3.44% | 2508/5421 |
| 近一季 | -6.43% | 2407/5231 |
| 近半年 | -2.01% | 1987/4920 |
| 近一年 | 1.06% | 2575/4394 |
| 近两年 | 43.88% | 1732/2954 |
| 近三年 | 26.26% | 1253/2253 |
| 成立以来 | 66.32% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.77% 3410/4961 |
11.98% 2258/5312 |
- - |
- - |
| 2025 | 18.48% 2312/4813 |
-1.10% 2577/3635 |
2.00% 1953/4076 |
17.50% 2485/4524 |
-0.05% 2326/4813 |
| 2024 | 16.13% 843/3463 |
2.79% 701/2808 |
-1.13% 944/3014 |
16.75% 1359/3129 |
-2.13% 1969/3463 |
| 2023 | -9.20% 1127/2656 |
4.07% 1056/2280 |
-3.88% 945/2385 |
-2.82% 754/2515 |
-6.60% 1842/2655 |
| 2022 | -19.68% 881/2207 |
-14.14% 909/1919 |
6.40% 711/2016 |
-13.57% 923/2113 |
1.73% 1163/2208 |
| 2021 | -2.87% 875/1822 |
-3.08% 754/1255 |
4.42% 889/1330 |
-5.59% 829/1466 |
1.66% 847/1822 |
| 2020 | 27.80% 571/1250 |
-9.65% 704/1028 |
13.25% 633/1067 |
10.46% 550/1164 |
13.07% 397/1184 |
| 2019 | 35.23% 382/1092 |
26.48% 406/754 |
-0.42% 261/804 |
0.79% 465/850 |
6.53% 598/918 |
| 2018 | -22.55% 245/834 |
- - |
- - |
- - |
-11.54% 312/691 |
| 2017 | 21.98% 156/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发沪深300ETF联接C VS. 长安沪深300非周期A(740101) |